4/A: Opus Genetics CEO Amends Stock Withholding Disclosure

Opus Genetics CEO George Magrath filed an amendment to clarify a stock transaction was for tax withholding, not an open market sale.

Summary

• George Magrath, CEO and Director of Opus Genetics, Inc. (IRD), filed an amendment to a previously reported transaction.
• The amendment clarifies that the disposition of 30,350 shares of Common Stock on November 1, 2025, was not an open market sale.
• The shares were withheld by the Issuer to satisfy tax withholding obligations related to a vesting and settlement event from a restricted stock units award.
• Following this transaction, George Magrath beneficially owns 1,291,654 shares of Common Stock.
• The shares were valued at $2.3 per share for tax withholding purposes.

Sentiment

Score: 5

Explanation: The filing is neutral as it is an amendment to clarify a routine, non-market insider transaction for tax withholding purposes, which does not indicate any change in company performance or outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Management Comments

• The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award.
• The reported transaction was not an open market sale of securities.

Industry Context

This filing pertains to a routine insider transaction clarification and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: Provides clarity on an insider transaction, confirming it was not a market sale, which may alleviate any potential misinterpretation of the original filing.

Key Dates

Recommendation

The filing is an amendment to clarify a routine tax withholding event related to restricted stock units and does not provide new information to alter the investment thesis for Opus Genetics. It confirms that the reported disposition was not an open market sale, which might alleviate any misinterpretation from the initial filing, thus warranting a 'hold' recommendation as no fundamental change is indicated.

Keywords

Opus Genetics, IRD, George Magrath, SEC Form 4/A, Insider Transaction, Stock Withholding, Restricted Stock Units, Beneficial Ownership